Incidence of febrile neutropenia and myelotoxicity of chemotherapy: A meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-hodgkin's lymphoma

Onkologie

Volumn 32, Issue 10, 2009, Pages 599-604

  Engert, Andreas ^a   Del Giglio, Auro ^b   Bias, Peter ^c   Lubenau, Heinz ^d   Gatzemeier, Ulrich ^e   Heigener, David ^e  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c TEVA PHARMACEUTICALS   (Israel)

^d BioGeneriX AG   (Germany)

^e Abteilung Pneumologie   (Germany)

Author keywords

Chemotherapy; Febrile neutropenia; Filgrastim; G CSF; XM02

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; XM 02;

ARTICLE; ATTRIBUTABLE RISK; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEBRILE NEUTROPENIA; HUMAN; LUNG CANCER; META ANALYSIS; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

COMORBIDITY; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; NEOPLASMS; NEUTROPENIA; RISK ASSESSMENT; RISK FACTORS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 70350759675     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232580     Document Type: Article

References (24)

1. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731.
2. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn JL, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
3. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan- Heijnen VC, Walewski J, Weber DC, Zielinski C: EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-2453.
4. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
5. Talcott JA, Finberg R, Mayer RJ, Goldman L: The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1998;148:2561-2568.
6. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.
7. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR; American Society of Clinical Oncology Growth Factors Expert Panel: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 2000;18: 3558-3585.
8. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
9. Riikonen P, Saarinen UM, Makipernaa A, Hovi L, Komulainen A, Pikhala J, Jalanko H: Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double-blind placebo-controlled study in children. Pediatr Infect Dis J 1994;13:197-202.
10. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Garcia-Ribas I: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803-808.
11. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R: Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-636.
12. Donnelly JP: Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. J Antimicrob Chemother 1993;31:813-829.
13. Savarese DM, Hsieh C, Stewart FM: Clinical impact of chemotherapy dose escalation in patients with hematological malignancies and solid tumors. J Clin Oncol 1997;15:2981-2995.
14. Phillips KA, Tannock IF: Design and interpretation of clinicals trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998;16:3179-3190.
15. Bokemeyer C, Kuczyk MA, Kohne H, Einsele H, Kynast B, Schmoll HJ: Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 1996;72:1-9.
16. Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, De Mulder PH, Stenning S, Lallemand E, De Prijck L, Collette L: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J Clin Oncol 1998;16:716-724.
17. ESMO recommendations for the application of haematopoietic growth factors (hGFs). Ann Oncol 2001;12:1219-1220.
18. Del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H: XM02 is superior to placebo and equivalent to NeupogenTM in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.
19. Gatzemeier U, Ciuleanu T, Dediu M, Ganea- Motan E, Lubenau H, del Giglio A: XM02, the first G-CSF biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small-cell or non-small-cell lung cancer receiving platinumbased chemotherapy. J Thorac Oncol 2009;4:736-740.
20. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A: XM02, the first G-CSF biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin-lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374-379.
21. Böhning D, Sarol JS: Estimating risk differences in multicenter studies under baseline-risk heterogeneity. Biometrics 2000;56:304-308.
22. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC: Prevention of chemotherapy- induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J Clin Oncol 2005;23:7974-7984.
23. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W: Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non- Hodgkin's lymphoma. Leuk Lymphoma 2003;44: 1503-1508. (Pubitemid 36833963)
24. George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC: Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1691-1696.